Peroxisome proliferator-activated receptor gamma
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peroxisome proliferator-activated receptor gamma as ChEMBL target CHEMBL2459, mapped to UniProt P37238. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Peroxisome proliferator-activated receptor gamma matters
Peroxisome proliferator-activated receptor gamma is reviewed as Peroxisome proliferator-activated receptor gamma (UniProt P37238); the current evidence base includes 5 approved drugs, 448 compounds, and 259 assays, with lead potency reaching pChEMBL 9.8.
Peroxisome proliferator-activated receptor gamma Sequence length is 505 aa.
Review this target as Peroxisome proliferator-activated receptor gamma, mapped to UniProt P37238. Sequence length is 505 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 5 approved drugs, 448 compounds, and 259 assays for this target. The dominant activity type is EC50. CHEMBL5207130 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL5207130 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Peroxisome proliferator-activated receptor gamma matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P37238, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5207130
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL107367
|
9.5 | EC50 | Clinical |
|
|
No preferred name
CHEMBL106666
|
8.9 | EC50 | — |
|
|
No preferred name
CHEMBL602468
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL3115237
|
8.5 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ROSIGLITAZONE
CHEMBL121
|
1999 |
|
|
PIOGLITAZONE
CHEMBL595
|
1999 |
|
|
TROGLITAZONE
CHEMBL408
|
1997 |